These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22035030)

  • 1. Future treatments for Parkinson's disease: surfing the PD pipeline.
    Hauser RA
    Int J Neurosci; 2011; 121 Suppl 2():53-62. PubMed ID: 22035030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacotherapy of Parkinson's disease: progress or regress?].
    Pytka K; Zygmunt M; Filipek B
    Postepy Hig Med Dosw (Online); 2013 Jul; 67():700-8. PubMed ID: 24018435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IPX066: a novel carbidopa-levodopa extended-release formulation.
    Hauser RA
    Expert Rev Neurother; 2012 Feb; 12(2):133-40. PubMed ID: 22288668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
    Hauser RA; Ellenbogen AL; Metman LV; Hsu A; O'Connell MJ; Modi NB; Yao HM; Kell SH; Gupta SK
    Mov Disord; 2011 Oct; 26(12):2246-52. PubMed ID: 21755537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease.
    Kestenbaum M; Fahn S
    Expert Opin Drug Saf; 2015 May; 14(5):761-7. PubMed ID: 25697185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New treatments for levodopa-induced motor complications.
    Rascol O; Perez-Lloret S; Ferreira JJ
    Mov Disord; 2015 Sep; 30(11):1451-60. PubMed ID: 26293004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Levodopa Formulations for Parkinson's Disease.
    Freitas ME; Ruiz-Lopez M; Fox SH
    CNS Drugs; 2016 Nov; 30(11):1079-1095. PubMed ID: 27743318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upcoming treatments in Parkinson's disease, including gene therapy.
    Rodnitzky RL
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S37-40. PubMed ID: 22166449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.
    Fernandez HH; Odin P
    Curr Med Res Opin; 2011 May; 27(5):907-19. PubMed ID: 21351823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New concepts in the treatment of Parkinson's disease.
    Ahlskog JE; Wilkinson JM
    Am Fam Physician; 1990 Feb; 41(2):574-84. PubMed ID: 1967895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of levodopa-induced motor complications.
    Stocchi F; Tagliati M; Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacological therapy of complicated Parkinson's disease].
    Jiménez-Jiménez FJ; Molina JA
    Rev Neurol; 1997 Aug; 25 Suppl 2():S170-9. PubMed ID: 9280685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in pharmacological therapy of Parkinson's disease.
    Riederer P; Lange KW; Youdim MB
    Adv Neurol; 1993; 60():626-35. PubMed ID: 8093582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recognition and treatment of response fluctuations in Parkinson's disease: review article.
    Verhagen Metman L
    Amino Acids; 2002; 23(1-3):141-5. PubMed ID: 12373528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.
    Pinna A; Wardas J; Simola N; Morelli M
    Life Sci; 2005 Nov; 77(26):3259-67. PubMed ID: 15979104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of motor fluctuations in Parkinson's disease: recent developments and future directions.
    Ramirez-Zamora A; Molho E
    Expert Rev Neurother; 2014 Jan; 14(1):93-103. PubMed ID: 24328720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
    Olanow CW; Jankovic J
    Mov Disord; 2005; 20 Suppl 11():S3-10. PubMed ID: 15822111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.